@article{Angula2022,
abstract = {A recent study identified quinolone-based thiosemicarbazone with an MIC90 value of 2 µM against Mycobacterium tuberculosis (Mtb). Herein, we report further optimization of the previous hit, which led to the discovery of quinolone-tethered aminoguanidine molecules with generally good antitubercular activity. Compounds 7f and 8e emerged as the hits of the series with submicromolar antitubercular activity, exhibiting MIC90 values of 0.49/0.90 and 0.49/0.60 µM, respectively, in the 7H9 CAS GLU Tx medium. This shows a fivefold increase in antitubercular activity compared to the previous study. Target compounds were also screened against ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens. However, the series generally exhibited poor antibacterial activities, with only compounds 8d and 8e demonstrating {\textgreater}50{\%} growth inhibition of Staphylococcus aureus and Pseudomonas aeruginosa at 32 µg/ml. The compounds displayed selective antitubercular activity as they showed no cytotoxicity effects against two noncancerous human cell lines. In silico studies predict 7f to have good solubility, no inhibitory effect on cytochrome P450 isoenzymes, and to be a non-pan-assay interfering compound.},
author = {Angula, Klaudia T and Legoabe, Lesetja J and Jordaan, Audrey and Warner, Digby F and Beteck, Richard M},
doi = {10.1002/ARDP.202200172},
issn = {1521-4184},
journal = {Archiv der Pharmazie},
keywords = {ESKAPE pathogens,aminoguanidine,fund{\_}not{\_}ack,original,quinolones,thiosemicarzone,tuberculosis},
mendeley-tags = {fund{\_}not{\_}ack,original},
month = {jun},
pages = {e2200172},
publisher = {John Wiley {\&} Sons, Ltd},
title = {{Investigation of quinolone-tethered aminoguanidine as novel antibacterial agents}},
url = {https://onlinelibrary.wiley.com/doi/full/10.1002/ardp.202200172 https://onlinelibrary.wiley.com/doi/abs/10.1002/ardp.202200172 https://onlinelibrary.wiley.com/doi/10.1002/ardp.202200172},
year = {2022}
}

{"_id":"i5vZSDi7jg3S2HbeG","bibbaseid":"angula-legoabe-jordaan-warner-beteck-investigationofquinolonetetheredaminoguanidineasnovelantibacterialagents-2022","author_short":["Angula, K. T","Legoabe, L. J","Jordaan, A.","Warner, D. F","Beteck, R. M"],"bibdata":{"bibtype":"article","type":"article","abstract":"A recent study identified quinolone-based thiosemicarbazone with an MIC90 value of 2 µM against Mycobacterium tuberculosis (Mtb). Herein, we report further optimization of the previous hit, which led to the discovery of quinolone-tethered aminoguanidine molecules with generally good antitubercular activity. Compounds 7f and 8e emerged as the hits of the series with submicromolar antitubercular activity, exhibiting MIC90 values of 0.49/0.90 and 0.49/0.60 µM, respectively, in the 7H9 CAS GLU Tx medium. This shows a fivefold increase in antitubercular activity compared to the previous study. Target compounds were also screened against ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens. However, the series generally exhibited poor antibacterial activities, with only compounds 8d and 8e demonstrating \\textgreater50% growth inhibition of Staphylococcus aureus and Pseudomonas aeruginosa at 32 µg/ml. The compounds displayed selective antitubercular activity as they showed no cytotoxicity effects against two noncancerous human cell lines. In silico studies predict 7f to have good solubility, no inhibitory effect on cytochrome P450 isoenzymes, and to be a non-pan-assay interfering compound.","author":[{"propositions":[],"lastnames":["Angula"],"firstnames":["Klaudia","T"],"suffixes":[]},{"propositions":[],"lastnames":["Legoabe"],"firstnames":["Lesetja","J"],"suffixes":[]},{"propositions":[],"lastnames":["Jordaan"],"firstnames":["Audrey"],"suffixes":[]},{"propositions":[],"lastnames":["Warner"],"firstnames":["Digby","F"],"suffixes":[]},{"propositions":[],"lastnames":["Beteck"],"firstnames":["Richard","M"],"suffixes":[]}],"doi":"10.1002/ARDP.202200172","issn":"1521-4184","journal":"Archiv der Pharmazie","keywords":"ESKAPE pathogens,aminoguanidine,fund_not_ack,original,quinolones,thiosemicarzone,tuberculosis","mendeley-tags":"fund_not_ack,original","month":"jun","pages":"e2200172","publisher":"John Wiley & Sons, Ltd","title":"Investigation of quinolone-tethered aminoguanidine as novel antibacterial agents","url":"https://onlinelibrary.wiley.com/doi/full/10.1002/ardp.202200172 https://onlinelibrary.wiley.com/doi/abs/10.1002/ardp.202200172 https://onlinelibrary.wiley.com/doi/10.1002/ardp.202200172","year":"2022","bibtex":"@article{Angula2022,\r\nabstract = {A recent study identified quinolone-based thiosemicarbazone with an MIC90 value of 2 µM against Mycobacterium tuberculosis (Mtb). Herein, we report further optimization of the previous hit, which led to the discovery of quinolone-tethered aminoguanidine molecules with generally good antitubercular activity. Compounds 7f and 8e emerged as the hits of the series with submicromolar antitubercular activity, exhibiting MIC90 values of 0.49/0.90 and 0.49/0.60 µM, respectively, in the 7H9 CAS GLU Tx medium. This shows a fivefold increase in antitubercular activity compared to the previous study. Target compounds were also screened against ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens. However, the series generally exhibited poor antibacterial activities, with only compounds 8d and 8e demonstrating {\\textgreater}50{\\%} growth inhibition of Staphylococcus aureus and Pseudomonas aeruginosa at 32 µg/ml. The compounds displayed selective antitubercular activity as they showed no cytotoxicity effects against two noncancerous human cell lines. In silico studies predict 7f to have good solubility, no inhibitory effect on cytochrome P450 isoenzymes, and to be a non-pan-assay interfering compound.},\r\nauthor = {Angula, Klaudia T and Legoabe, Lesetja J and Jordaan, Audrey and Warner, Digby F and Beteck, Richard M},\r\ndoi = {10.1002/ARDP.202200172},\r\nissn = {1521-4184},\r\njournal = {Archiv der Pharmazie},\r\nkeywords = {ESKAPE pathogens,aminoguanidine,fund{\\_}not{\\_}ack,original,quinolones,thiosemicarzone,tuberculosis},\r\nmendeley-tags = {fund{\\_}not{\\_}ack,original},\r\nmonth = {jun},\r\npages = {e2200172},\r\npublisher = {John Wiley {\\&} Sons, Ltd},\r\ntitle = {{Investigation of quinolone-tethered aminoguanidine as novel antibacterial agents}},\r\nurl = {https://onlinelibrary.wiley.com/doi/full/10.1002/ardp.202200172 https://onlinelibrary.wiley.com/doi/abs/10.1002/ardp.202200172 https://onlinelibrary.wiley.com/doi/10.1002/ardp.202200172},\r\nyear = {2022}\r\n}\r\n","author_short":["Angula, K. T","Legoabe, L. J","Jordaan, A.","Warner, D. F","Beteck, R. M"],"key":"Angula2022","id":"Angula2022","bibbaseid":"angula-legoabe-jordaan-warner-beteck-investigationofquinolonetetheredaminoguanidineasnovelantibacterialagents-2022","role":"author","urls":{"Paper":"https://onlinelibrary.wiley.com/doi/full/10.1002/ardp.202200172 https://onlinelibrary.wiley.com/doi/abs/10.1002/ardp.202200172 https://onlinelibrary.wiley.com/doi/10.1002/ardp.202200172"},"keyword":["ESKAPE pathogens","aminoguanidine","fund_not_ack","original","quinolones","thiosemicarzone","tuberculosis"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh","6GMFi5DCojy3jHY44"],"keywords":["eskape pathogens","aminoguanidine","fund_not_ack","original","quinolones","thiosemicarzone","tuberculosis"],"search_terms":["investigation","quinolone","tethered","aminoguanidine","novel","antibacterial","agents","angula","legoabe","jordaan","warner","beteck"],"title":"Investigation of quinolone-tethered aminoguanidine as novel antibacterial agents","year":2022}